Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2020 Jul 17

PMID 32669869

Citations 6

Authors

Mona Kotecha

William P Cheshire

Helen Finnigan

Kathryn Giblin

Himanshu Naik

Joanne Palmer

Simon Tate

Joanna M Zakrzewska

Affiliations

Soon will be listed here.

Abstract

Purpose: Vixotrigine (BIIB074) is a voltage- and use-dependent sodium channel blocker. These studies will evaluate the efficacy and safety of vixotrigine in treating pain experienced by patients with trigeminal neuralgia (TN) using enriched enrollment randomized withdrawal trial designs.

Patients And Methods: Two double-blind randomized withdrawal studies are planned to evaluate the efficacy and safety of vixotrigine compared with placebo in participants with TN (NCT03070132 and NCT03637387). Participant criteria include ≥18 years old who have classical, purely paroxysmal TN diagnosed ≥3 months prior to study entry, who experience ≥3 paroxysms of pain/day. The two studies will include a screening period, 7-day run-in period, a 4- or 6-week single-dose-blind dose-optimization period (Study 1) or 4-week open-label period (Study 2), and 14-week double-blind period. Participants will receive vixotrigine 150 mg orally three times daily in the dose-optimization and open-label periods. The primary endpoint of both studies is the proportion of participants classified as responders at Week 12 of the double-blind period. Secondary endpoints include safety measures, quality of life, and evaluation of vixotrigine population pharmacokinetics.

Conclusion: There is a need for an effective, well-tolerated, noninvasive treatment for the neuropathic pain associated with TN. The proposed studies will evaluate the efficacy and safety of vixotrigine in treating pain experienced by patients with TN.

Citing Articles

Discordance between preclinical and clinical testing of Na V 1.7-selective inhibitors for pain.

Yang J, Xie Y, Smith R, Ratte S, Prescott S Pain. 2025; 166(3):481-501.

PMID: 39928833 PMC: 11808711. DOI: 10.1097/j.pain.0000000000003425.

Nanomedicine and voltage-gated sodium channel blockers in pain management: a game changer or a lost cause?.

Le Franc A, Da Silva A, Lepetre-Mouelhi S Drug Deliv Transl Res. 2024; 14(8):2112-2145.

PMID: 38861139 DOI: 10.1007/s13346-024-01615-9.

Neuropathic pain; what we know and what we should do about it.

Smith P Front Pain Res (Lausanne). 2023; 4:1220034.

PMID: 37810432 PMC: 10559888. DOI: 10.3389/fpain.2023.1220034.

Identification and targeting of a unique Na1.7 domain driving chronic pain.

Gomez K, Stratton H, Duran P, Loya S, Tang C, Calderon-Rivera A Proc Natl Acad Sci U S A. 2023; 120(32):e2217800120.

PMID: 37498871 PMC: 10410761. DOI: 10.1073/pnas.2217800120.

Targeted Therapy for Orofacial Pain: A Novel Perspective for Precision Medicine.

Raman S, Ikutame D, Okura K, Matsuka Y J Pers Med. 2023; 13(3).

PMID: 36983746 PMC: 10057163. DOI: 10.3390/jpm13030565.

References

Farrar J, Young Jr J, Lamoreaux L, Werth J, Poole M . Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001; 94(2):149-158. DOI: 10.1016/S0304-3959(01)00349-9. View

Zakrzewska J, Palmer J, Morisset V, Giblin G, Obermann M, Ettlin D . Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017; 16(4):291-300. DOI: 10.1016/S1474-4422(17)30005-4. View

Sandhu S, Lee J . Measurement of Trigeminal Neuralgia Pain: Penn Facial Pain Scale. Neurosurg Clin N Am. 2016; 27(3):327-36. DOI: 10.1016/j.nec.2016.02.003. View

Stefano G, La Cesa S, Truini A, Cruccu G . Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain. 2014; 15:34. PMC: 4067104. DOI: 10.1186/1129-2377-15-34. View

Symonds T, Randall J, Hoffman D, Zakrzewska J, Gehringer W, Lee J . Measuring the impact of trigeminal neuralgia pain: the Penn Facial Pain Scale-Revised. J Pain Res. 2018; 11:1067-1073. PMC: 5993035. DOI: 10.2147/JPR.S152958. View

Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K . Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology. 2008; 71(15):1183-90. DOI: 10.1212/01.wnl.0000326598.83183.04. View

Cruccu G, Finnerup N, Jensen T, Scholz J, Sindou M, Svensson P . Trigeminal neuralgia: New classification and diagnostic grading for practice and research. Neurology. 2016; 87(2):220-8. PMC: 4940067. DOI: 10.1212/WNL.0000000000002840. View

Besi E, Boniface D, Cregg R, Zakrzewska J . Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). J Headache Pain. 2015; 16:563. PMC: 4558989. DOI: 10.1186/s10194-015-0563-z. View

Zakrzewska J . Multi-dimensionality of chronic pain of the oral cavity and face. J Headache Pain. 2013; 14:37. PMC: 3642003. DOI: 10.1186/1129-2377-14-37. View

10.

Dworkin R, Turk D, Peirce-Sandner S, Baron R, Bellamy N, Burke L . Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010; 149(2):177-193. DOI: 10.1016/j.pain.2010.02.018. View

11.

. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33(9):629-808. DOI: 10.1177/0333102413485658. View

12.

Crofford L, Mease P, Simpson S, Young Jr J, Martin S, Haig G . Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008; 136(3):419-431. DOI: 10.1016/j.pain.2008.02.027. View

13.

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

14.

Zakrzewska J, Wu J, Mon-Williams M, Phillips N, Pavitt S . Evaluating the impact of trigeminal neuralgia. Pain. 2017; 158(6):1166-1174. DOI: 10.1097/j.pain.0000000000000853. View

15.

Tentolouris-Piperas V, Lee G, Reading J, OKeeffe A, Zakrzewska J, Cregg R . Adverse effects of anti-epileptics in trigeminal neuralgiform pain. Acta Neurol Scand. 2018; 137(6):566-574. DOI: 10.1111/ane.12901. View

16.

Zakrzewska J, Palmer J, Bendtsen L, Stefano G, Ettlin D, Maarbjerg S . Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience. Trials. 2018; 19(1):704. PMC: 6307274. DOI: 10.1186/s13063-018-3045-1. View

17.

Katusic S, Beard C, Bergstralh E, Kurland L . Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol. 1990; 27(1):89-95. DOI: 10.1002/ana.410270114. View

18.

Moore R, Wiffen P, Eccleston C, Derry S, Baron R, Bell R . Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain. 2015; 156(8):1382-1395. DOI: 10.1097/j.pain.0000000000000088. View

19.

Bendtsen L, Zakrzewska J, Abbott J, Braschinsky M, Di Stefano G, Donnet A . European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019; 26(6):831-849. DOI: 10.1111/ene.13950. View

20.

Zakrzewska J, Linskey M . Trigeminal neuralgia. BMJ. 2014; 348:g474. DOI: 10.1136/bmj.g474. View